Treatment of Vertigo: A Randomized, Double-Blind Trial Comparing Efficacy and Safety of Ginkgo biloba Extract EGb 761 and Betahistine

Larysa Sokolova, Robert Hoerr, Tamara Mishchenko, Larysa Sokolova, Robert Hoerr, Tamara Mishchenko

Abstract

A multicenter clinical trial was performed to compare the efficacy and safety of Ginkgo biloba extract EGb 761 and betahistine at recommended doses in patients with vertigo. One hundred and sixty patients (mean age 58 years) were randomly assigned to double-blind treatment with EGb 761 (240 mg per day) or betahistine (32 mg per day) for 12 weeks. An 11-point numeric analogue scale, the Vertigo Symptom Scale-short form, the Clinical Global Impression Scales and the Sheehan Disability Scale were used as outcome measures. Both treatment groups were comparable at baseline and improved in all outcome measures during the course of treatment. There was no significant intergroup difference with regard to changes in any outcome measure. Numerically, improvements of patients receiving EGb 761 were slightly more pronounced on all scales. Clinical global impression was rated "very much improved" or "much improved" in 79% of patients treated with EGb 761 and in 70% receiving betahistine. With 27 adverse events in 19 patients, EGb 761 showed better tolerability than betahistine with 39 adverse events in 31 patients. In conclusion, the two drugs were similarly effective in the treatment of vertigo, but EGb 761 was better tolerated. This trial is registered with controlled-trials.com ISRCTN02262139.

Figures

Figure 1
Figure 1
Patient disposition and analysis sets.
Figure 2
Figure 2
Response rates, defined as clinician's global impression (CGI) rated “much improved” or “very much improved” or patient's rating of NAS improvement at least 50%.
Figure 3
Figure 3
Proportion of patients with nystagmus before and after treatment.
Figure 4
Figure 4
Proportion of patients with different grades of swaying in the Romberg test before and after treatment.
Figure 5
Figure 5
Proportion of patients with different grades of rotation in Unterberger's stepping test before and after treatment.

References

    1. Neuhauser HK, Radtke A, von Brevern M, Lezius F, Feldmann M, Lempert T. Burden of dizziness and vertigo in the community. Archives of Internal Medicine. 2008;168(19):2118–2124.
    1. Newman-Toker DE, Hsieh Y, Camargo CA, Jr., Pelletier AJ, Butchy GT, Edlow JA. Spectrum of dizziness visits to US emergency departments: Cross-sectional analysis from a nationally representative sample. Mayo Clinic Proceedings. 2008;83(7):765–775.
    1. Strupp M, Brandt T. Diagnosis and treatment of vertigo and dizziness. Deutsches Ärzteblatt International. 2008;105(10):173–180.
    1. Hanley K, O'Dowd T, Considine N. A systematic review of vertigo in primary care. British Journal of General Practice. 2001;51(469):666–671.
    1. Okroglic S, Widmann CN, Urbach H, Scheltens P, Heneka MT. Clinical symptoms and risk factors in cerebral microangiopathy patients. PLoS ONE. 2013;8(2)e53455
    1. Agus S, Benecke H, Thum C, Strupp M. Clinical and demographic features of vertigo: findings from the REVERT registry. Frontiers in Neurology. 2013;4, article 48
    1. Della Pepa C, Guidetti G, Eandi M. Betahistine in the treatment of vertiginous syndromes: a meta-analysis. Acta Otorhinolaryngologica Italica. 2006;26(4):208–215.
    1. James AL, Burton MJ. Betahistine for Ménière's disease or syndrome. Cochrane Database of Systematic Reviews. 2001;(1)CD001873
    1. Heiss WD, Zeiler K. Medikamentöse Beeinflussung der Hirndurchblutung [The influence on drugs on cerebral blood flow] Pharmakotherapie. 1978;1(3):137–144.
    1. Maass B, Silberzahn J, Simon R. Zur Wirkung von Ginkgo-biloba—Extrakt (Tebonin) auf die Wasserstoff-Auswaschvorgänge an der Cochleabasis unter hypotensiver Ischämie. Extracta Otorhinolaryngologica. 1987;9(5):169–172.
    1. Huang S, Jeng C, Kao S, Yu JJ, Liu D. Improved haemorrheological properties by Ginkgo biloba extract (Egb 761) in type 2 diabetes mellitus complicated with retinopathy. Deutsches Ärzteblatt International. 2004;23(4):615–621.
    1. Tchantchou F, Xu Y, Wu Y, Christen Y, Luo Y. EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer's disease. The FASEB Journal. 2007;21(10):2400–2408.
    1. Abdel-Kader R, Hauptmann S, Keil U, et al. Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761) Pharmacological Research. 2007;56(6):493–502.
    1. Abdel-Wahab BA, Abd El-Aziz SM. Ginkgo biloba protects against intermittent hypoxia-induced memory deficits and hippocampal DNA damage in rats. Phytomedicine. 2012;19(5):444–450.
    1. Hamann KF. Ginkgo special extract EGb 761 in vertigo: a systematic review of randomised , double-blind, placebo-controlled clinical trials. The Internet Journal of Otorhinolaryngology. 2007;6(2):258–263.
    1. World Health Organization. International Statistical Classification of Diseases and Related Health Problems. Geneva, Switzerland: World Health Organization; 1992.
    1. Yardley L, Masson E, Verschuur C, Haacke N, Luxon L. Symptoms, anxiety and handicap in dizzy patients: development of the Vertigo symptom scale. Journal of Psychosomatic Research. 1992;36(8):731–741.
    1. Sheehan DV. The Anxiety Disease. New York, NY, USA: Charles Scribner's Sons; 1983.
    1. NIMH National Institute of Mental Health. 028 CGI. Clinical global impressions. In: Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Rockville, Md, USA: NIMH; 1976. pp. 218–222.
    1. Strupp M, Hupert D, Frenzel C, et al. Long-term prophylactic treatment of attacks of vertigo in Meniére's disease—comparison of a high with a low dosage of betahistine in an open trial. Acta Oto-Laryngologica. 2008;128(5):520–524.
    1. Nauta JJP. Meta-analysis of clinical studies with betahistine in Ménière's disease and vestibular vertigo. European Archives of Otorhinolaryngology. 2014;271(5):887–897.
    1. Beraneck M, Idoux E. Reconsidering the role of neuronal intrinsic properties and neuromodulation in vestibular homeostasis. Frontiers in Neurology. 2012;3, article 25:13 pages.
    1. Papegaaij S, Taube W, Baudry S, Otten E, Hortobágyi T. Aging cuases a reorganization of cortical and spinal control of posture. Frontiers in Aging Neuroscience. 2014;6, article 28
    1. Shao M, Hirsch JC, Peusner KD. Plasticity of spontaneous excitatory and inhibitory synaptic activity in morphologically defined vestibular nuclei neurons during early vestibular compensation. Journal of Neurophysiology. 2012;107(1):29–41.
    1. Müller WE, Heiser J, Leuner K. Effects of the standardized Ginkgo biloba extract EGb 761 on neuroplasticity. International Psychogeriatrics. 2012;24(supplement 1):S21–S24.
    1. Lacour M, Ez-Zaher L, Raymond J. Plasticity mechanisms in vestibular compensation in the cat are improved by an extract of Ginkgo biloba (EGb 761) Pharmacology Biochemistry and Behavior. 1991;40(2):367–379.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir